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Progressive telomere shortening pro-
vides the mechanism by which normal
human cells count divisions and eventu-
ally stop proliferating due to replicative
senescence (Shay and Wright, 2004).
Cancer cells require multiple mutations
to become malignant, and each mutation
initially occurs in a single cell and uses
up many divisions before it can become
widespread in a premalignant popula-
tion. It is believed that the primary pur-
pose of replicative aging is to form a
barrier against the continuing prolifera-
tion of precancerous cells, since limiting
the total number of available doublings
would prevent cells that had divided
many times during the acquisition of a
few mutations from progressing to frank
malignancy. The demonstration that the
vast majority of cancers have upregulat-
ed telomerase in order to overcome
these limits (Kim et al., 1994; Shay and
Bacchetti, 1997) and that inhibiting telo-
merase in cultured cancer cells can drive
them into crisis and apoptosis (Hahn et
al., 1999; Herbert et al., 1999; Zhang et
al., 1999; Shay and Wright, 2002, 2004)
raises great hopes that inhibiting telo-
merase will provide a very effective can-
cer treatment. Telomerase inhibitors will
have a high therapeutic ratio, since most
normal human cells do not express telo-
merase, and telomerase inhibitors will be
almost universal, since 85%–90% of all
tumors express telomerase.
As our understanding of telomere
biology increases, it is becoming clear
that it is the shortest telomeres rather
than average telomere length that cause
chromosome end fusions and apoptosis
in telomerase-inhibited cancer cells in
crisis. This explains why most cancer
cells have relatively short telomeres,
since to a first approximation they only
need enough telomerase to prevent the
shortest telomeres from causing prob-
lems. Once a cancer cell upregulates
telomerase sufficiently to maintain its
shortest telomeres, there may be little
additional advantage in increasing its
expression in order to further elongate
telomeres. It is now known that most
human stem cells express telomerase,
and there is some concern over the con-
sequences to stem cells from inhibiting
telomerase. However, most stem cells
have telomeres much longer than most
cancer cells, and most primitive stem
cells may divide less frequently than can-
cer cells (so their rate of telomere short-
ening per calendar time in the absence
of telomerase is predicted to be much
less than cancer cells). It is hoped that
the combination of longer initial telomere
length and slower rates of shortening
would provide a large therapeutic win-
dow between the effects of inhibiting
telomerase in stem versus cancer cells.
The maintenance of telomere length
in telomerase-expressing cells reflects
the equal balance of telomere-shorten-
ing and lengthening activities. In addition
to the amount of telomerase, a large
number of factors have been found that
influence the efficiency with which telo-
merase is actually recruited to act on
telomeres. Some of the telomere-binding
factors and proteins associated with telo-
merase are shown in Figure 1. TRF1
(telomere repeat factor 1) was the first
human telomere binding protein to be
identified, and it was quickly shown to be
a negative regulator of telomerase: over-
expressing TRF1 causes telomeres in
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Inhibition of telomerase is an exciting therapeutic target, since it is required for the long-term proliferation of most cancer
cells but not present in most somatic cells. However, effective telomerase inhibitors have yet to be tested in clinical trials. In
this issue of Cancer Cell, Seimiya and coworkers (Seimiya et al., 2005) explore inhibiting tankyrase, an enzyme involved in
making telomeres accessible to telomerase. Adding a partial inhibition of tankyrase to a partial inhibition of telomerase
drove cancer cells into crisis and death.The combination of tankyrase and telomerase inhibitors may offer new opportuni-
ties for realizing the promise of telomerase inhibition therapy.
Figure 1. Tankyrase and accessibility of
telomerase to telomeres
The telosomal complex is composed of the
major double-stranded telomere binding
proteins TRF1 and TRF2, associating through
TIN2 and a POT1 interacting protein (PIP1,
also known at PTOP and TINT1) with the sin-
gle-stranded TTAGGG binding protein POT1.
Tankyrase ADP-ribosylates TRF1, which may
lead to a more open configuration allowing
telomerase to have access to the single
strand G-rich overhang. In the presence of a
tankyrase inhibitor, the telosomal complex
maintains a well-packaged telomere result-
ing in a configuration that is not favorable for
telomerase access to the telomere. Many
additional telomere/telomerase-interacting
proteins are not shown.
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cancer cells to shorten to a new reduced
maintenance length, while dominant-
negative TRF1 that removes wild-type
TRF1 from telomeres causes telomere
elongation (van Steensel and de Lange,
1997). TRF2 is the second major factor
that binds to double-stranded telomeric
DNA, and a host of factors interacting
with either TRF1 or TRF2 have been
identified. Recent discoveries that one of
the proteins, TIN2, interacts with both
TRF1 and TRF2 have led to the concept
that there is a large multimolecular com-
plex of mutually interacting factors (Ye et
al., 2004; Liu et al., 2004; Houghtaling et
al., 2004), so that it is now difficult to
ascribe effects to the function of single
factors distinguishable from their effects
on the organization of the whole telomer-
ic packaging structure.
Tankyrase was originally identified
based on its ability to interact with
TRF1, but it also has other nontelomeric
functions. Tankyrase is a member of the
PARP family that can ADP-ribosylate
TRF1 and cause it to lose its ability to
bind DNA (Smith et al., 1998). ADP-
ribosylated TRF1 is rapidly ubiquitinated
and degraded. Tankyrase is a relatively
abundant cytoplasmic protein that is
largely excluded from the nucleus (lacks
a nuclear localization signal), and may
enter the nucleus during S phase
through interactions with TRF1 in order
to remove telomere binding proteins
from blocking progression of the 
replication complex. Overexpression of
tankyrase with an exogenous nuclear
localization signal produces telomere
elongation in telomerase-expressing
cells, consistent with a functional reduc-
tion in TRF1 complexes on telomeres
resulting from their ADP ribosylation by
tankyrase (Smith et al., 1998).
Although many cultured cancer cells
can be driven into crisis by concentra-
tions of telomerase inhibitors that only
reduce telomerase activity by 50%–80%,
we and others have observed tumor lines
in which an 80% inhibition only resulted
in telomeres shortening until a stable but
reduced telomere length was achieved
(our unpublished data). This reflects the
fact that telomerase is recruited more effi-
ciently to short telomeres, perhaps due to
reduced binding of the multicomponent
telomeric complex. As telomeres shorten,
a small amount of telomerase activity can
sometimes be recruited sufficiently well
so that a new balance between shorten-
ing and lengthening rates is achieved.
The paper by Seimiya et al. (2005) 
in this issue exploits the knowledge of
tankyrase action by asking whether
manipulating the ability to recruit telomer-
ase to act on telomeres could prevent the
establishment of a new telomere equilib-
rium maintenance length.
These authors used a telomerase
inhibitor called MST-312, a chemical
derivative of a component of green tea
(Seimiya et al., 2002). Although higher
concentrations of MST-312 (2 µM) inhib-
ited telomerase efficiently and were able
to drive tumor cells into crisis, Seimiya
and colleagues found that lower concen-
trations (0.75 µM) only partially inhibited
telomerase, and while telomeres short-
ened from 5 kb to a new stable length of
almost 4 kb, the cells continued to prolif-
erate. Seimiya et al. (2005) then picked a
dose of 3-aminobenzamide (a general
PARP inhibitor that inhibits tankyrase)
that had minimal effects on the growth
rate of the control cells. They then
demonstrated that adding 3-aminoben-
zamide to the MST-312-exposed cells
with reset telomeres at 4 kb caused them
to begin shortening again until the cells
entered crisis and died.This dramatically
demonstrates that combinations of
tankyrase and telomerase inhibitors at
nontoxic doses may be an effective anti-
cancer therapeutic approach.
In summary, changes in telomere
function have been implicated in both
human aging and cancer. Telomeres are
essential for proper chromosomal repli-
cation, and, through proteins that bind to
telomeric DNA and recruit/modify other
proteins, maintain the integrity of the
genome by preventing chromosomal
recombination, end-end fusions, and
degradation. Telomerase is a cellular
reverse transcriptase enzyme complex
that is not expressed in most normal
human cells but is required for the long-
term growth of almost all malignant
human cancers. Telomerase is regulated
in cis by telomere-associated proteins,
and inhibition of telomerase results in
progressive telomere shortening, lead-
ing to chromosome instability, cell cycle
arrest, and apoptosis. The study by
Seimiya et al. (2005) illustrates a new
strategy for telomere-based molecular
cancer therapeutics.
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